Impact of XIAP protein levels on the survival of myeloma cells

1 INSERM, UMR 892, Nantes, France 2 Nantes Atlantique Universités, Nantes, Cedex, France 3 Hematology 4 Internal Medicine, Department of Internal Medicine and Biomedical Science, Universita degli Studi di Parma, Parma, Italy Correspondence: Sophie Barillé-Nion, UMR 892, 9 quai Moncousu, Nantes, F-44093, France., E-mail: sbarille{at}nantes.inserm.fr Background: XIAP is the best characterized and the most potent direct endogenous caspase inhibitor and is considered a key actor in the control of apoptotic threshold in cancer cells. In this report, we specifically addressed XIAP regulation and function in myeloma cells. Design and Methods: XIAP and its endogenous inhibitor XAF-1 protein levels and their regulation were assessed by immunoblot analysis in myeloma cell lines or primary myeloma cells. XIAP knockdown by RNA interference was used to evaluate XIAP impact on in vitro drug sensitivity and in vivo tumor growth. Results: Our results indicate that myeloma cells expressed high levels of XIAP protein that were tightly regulated during growth factor stimulation or stress condition. Of note, an increased XIAPlevel was evidenced during the blockade of the canonical cap-dependent translation by the mTOR inhibitor rapamycin, supporting the hypothesis of a functional IRES sequence in XIAP mRNA. In addition, caspase-mediated XIAP cleavage correlated to an apoptotic process occurring upon cell treatment with the proteasome inhibitor bortezomib. Importantly, XIAP knockdown using RNA interference enhanced drug sensitivity and decreased tumor formation in NOD/SCID mice. Finally, myeloma cells also expressed the XIAP inhibitor XAF-1 that interacted with XIAP in viable myeloma cells. Conclusions: Altogether, our data argue for a delicate control of XIAP function in myeloma cells and stimulate interest in targeting XIAP in myeloma treatment. Key words: XIAP, myeloma, apoptosis.